458 related articles for article (PubMed ID: 34419621)
1. Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo.
Albanese F; Mercatelli D; Finetti L; Lamonaca G; Pizzi S; Shimshek DR; Bernacchia G; Morari M
Neurobiol Dis; 2021 Nov; 159():105487. PubMed ID: 34419621
[TBL] [Abstract][Full Text] [Related]
2. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
[TBL] [Abstract][Full Text] [Related]
3. Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA).
Ho PW; Leung CT; Liu H; Pang SY; Lam CS; Xian J; Li L; Kung MH; Ramsden DB; Ho SL
Autophagy; 2020 Feb; 16(2):347-370. PubMed ID: 30983487
[TBL] [Abstract][Full Text] [Related]
4. G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice.
Novello S; Arcuri L; Dovero S; Dutheil N; Shimshek DR; Bezard E; Morari M
Neurobiol Dis; 2018 Dec; 120():21-33. PubMed ID: 30172844
[TBL] [Abstract][Full Text] [Related]
5. LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease.
Pang SY; Lo RCN; Ho PW; Liu HF; Chang EES; Leung CT; Malki Y; Choi ZY; Wong WY; Kung MH; Ramsden DB; Ho SL
Transl Neurodegener; 2022 Jan; 11(1):5. PubMed ID: 35101134
[TBL] [Abstract][Full Text] [Related]
6. The Effect of p.G2019S Mutation in the
Usenko TS; Timofeeva A; Beletskaia M; Basharova K; Baydakova G; Bezrukova A; Grunina M; Emelyanov A; Miliukhina I; Zakharova E; Pchelina S
J Integr Neurosci; 2024 Jan; 23(1):16. PubMed ID: 38287861
[TBL] [Abstract][Full Text] [Related]
7. LRRK2 impairs autophagy by mediating phosphorylation of leucyl-tRNA synthetase.
Ho DH; Kim H; Nam D; Sim H; Kim J; Kim HG; Son I; Seol W
Cell Biochem Funct; 2018 Dec; 36(8):431-442. PubMed ID: 30411383
[TBL] [Abstract][Full Text] [Related]
8. LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson's disease patients.
Ysselstein D; Nguyen M; Young TJ; Severino A; Schwake M; Merchant K; Krainc D
Nat Commun; 2019 Dec; 10(1):5570. PubMed ID: 31804465
[TBL] [Abstract][Full Text] [Related]
9. Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons.
Schapansky J; Khasnavis S; DeAndrade MP; Nardozzi JD; Falkson SR; Boyd JD; Sanderson JB; Bartels T; Melrose HL; LaVoie MJ
Neurobiol Dis; 2018 Mar; 111():26-35. PubMed ID: 29246723
[TBL] [Abstract][Full Text] [Related]
10. Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson's disease brains with Lewy body pathology.
Mamais A; Manzoni C; Nazish I; Arber C; Sonustun B; Wray S; Warner TT; Cookson MR; Lewis PA; Bandopadhyay R
Brain Res; 2018 Dec; 1701():75-84. PubMed ID: 30055128
[TBL] [Abstract][Full Text] [Related]
11. Lysosomal Pathogenesis of Parkinson's Disease: Insights From LRRK2 and GBA1 Rodent Models.
Volta M
Neurotherapeutics; 2023 Jan; 20(1):127-139. PubMed ID: 36085537
[TBL] [Abstract][Full Text] [Related]
12. G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons.
Volpicelli-Daley LA; Abdelmotilib H; Liu Z; Stoyka L; Daher JP; Milnerwood AJ; Unni VK; Hirst WD; Yue Z; Zhao HT; Fraser K; Kennedy RE; West AB
J Neurosci; 2016 Jul; 36(28):7415-27. PubMed ID: 27413152
[TBL] [Abstract][Full Text] [Related]
13. Dopamine Transporter, PhosphoSerine129 α-Synuclein and α-Synuclein Levels in Aged LRRK2 G2019S Knock-In and Knock-Out Mice.
Domenicale C; Mercatelli D; Albanese F; Novello S; Vincenzi F; Varani K; Morari M
Biomedicines; 2022 Apr; 10(4):. PubMed ID: 35453631
[TBL] [Abstract][Full Text] [Related]
14. Glucocerebrosidase 1 and leucine-rich repeat kinase 2 in Parkinson disease and interplay between the two genes.
Lee CY; Menozzi E; Chau KY; Schapira AHV
J Neurochem; 2021 Dec; 159(5):826-839. PubMed ID: 34618942
[TBL] [Abstract][Full Text] [Related]
15. In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity.
Novello S; Mercatelli D; Albanese F; Domenicale C; Brugnoli A; D'Aversa E; Vantaggiato S; Dovero S; Murtaj V; Presotto L; Borgatti M; Shimshek DR; Bezard E; Moresco RM; Belloli S; Morari M
Neurobiol Dis; 2022 Jan; 162():105579. PubMed ID: 34871735
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of the p53-p21 pathway by G2019S LRRK2 contributes to the cellular senescence and accumulation of α-synuclein.
Ho DH; Seol W; Son I
Cell Cycle; 2019 Feb; 18(4):467-475. PubMed ID: 30712480
[TBL] [Abstract][Full Text] [Related]
17. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation.
Zhao Y; Keshiya S; Perera G; Schramko L; Halliday GM; Dzamko N
Neurobiol Dis; 2020 Oct; 144():105049. PubMed ID: 32800998
[TBL] [Abstract][Full Text] [Related]
18. Seventy-Two-Hour LRRK2 Kinase Activity Inhibition Increases Lysosomal GBA Expression in H4, a Human Neuroglioma Cell Line.
Ruz C; Alcantud JL; Vives F; Arrebola F; Hardy J; Lewis PA; Manzoni C; Duran R
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805938
[TBL] [Abstract][Full Text] [Related]
19. Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease.
Magalhaes J; Gegg ME; Migdalska-Richards A; Doherty MK; Whitfield PD; Schapira AH
Hum Mol Genet; 2016 Aug; 25(16):3432-3445. PubMed ID: 27378698
[TBL] [Abstract][Full Text] [Related]
20. Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway.
Tong Y; Giaime E; Yamaguchi H; Ichimura T; Liu Y; Si H; Cai H; Bonventre JV; Shen J
Mol Neurodegener; 2012 Jan; 7():2. PubMed ID: 22230652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
